Abstract: The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes.

Abstract: The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes.

Abstract: Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one tigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups. Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Abstract: Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide fragment having approximately between 10 and 40 amino acids and comprising at least one antigenic determinant and also comprising one or more chains derived from fatty acids and one or more modified steroid groups useful for immunizing a human or animal body against pathogenic agents such as viruses or parasites which fragment is preferably a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Abstract: Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one antigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups.Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses. DA.

Abstract: The invention relates to cloning of the gene for the toxoplasma GP28.5 anen. It also encompasses purified GP28.5 antigen preparations and antigenic polypeptides derived from said antigen, and their applications.

Abstract: Peptide fragment of M protein of S. pyrogenes elecit opsonic antibodies which are type-specific for type 24 streptococci.

Abstract: The invention relates to novel synthetic peptides, process for their peparation and their application to the production of antibodies.These peptides include at the most 18 amino-acids and at the least 4 amino-acids in which n is equal to 1 or 2, and when n equals 1 the peptidic sequence P is contained in the following peptidic chain:Asn-Thr-Phe-Tyr-Cys-Cys-Glu-Leu-Cys-Cys-A-Pro-Ala-Cys-Ala-Gly-Cys-Tin which either A represents Asn and T represents Tyr, or A represents Tyr and T represents Asn and in which the thiol groups of the possible cysteyl residues are protected by groups stable under biological conditions. Use for the production of antibodies capable of replacing biological activity particularly of enterotoxins produced by Escherichia coli strains.